Alba Toll1, Anna Mané1. 1. Alba Toll, Anna Mané, Institut de Neuropsiquitria i Addiccions, Parc de Salut Mar, 08003 Barcelona, Spain.
Abstract
AIM: To systematically review studies measuring peripheric brain-derived neurotrophic factor (BDNF) levels on first-episode psychosis patients and variables related to them. METHODS: A systematic search was made of articles published in the Medline database from 2002 up to June 2014. Included are original studies that report enzyme-linked immunosorbent assay measurement of BDNF levels in serum or plasma in patients with a diagnosis of first episode psychosis (FEP) and age- and gender- matched healthy controls. RESULTS: Of the initially identified 147 articles, only 18 satisfied the inclusion criteria. Of this, 15 found a significant reduction in patients with FEP compared with age- and gender - matched controls. CONCLUSION: Peripheral BDNF levels are generally reduced in FEP patients. There are some factors that may influence BDNF levels that need to be further studied. Furthermore, a future meta-analysis in this topic is needed.
AIM: To systematically review studies measuring peripheric brain-derived neurotrophic factor (BDNF) levels on first-episode psychosispatients and variables related to them. METHODS: A systematic search was made of articles published in the Medline database from 2002 up to June 2014. Included are original studies that report enzyme-linked immunosorbent assay measurement of BDNF levels in serum or plasma in patients with a diagnosis of first episode psychosis (FEP) and age- and gender- matched healthy controls. RESULTS: Of the initially identified 147 articles, only 18 satisfied the inclusion criteria. Of this, 15 found a significant reduction in patients with FEP compared with age- and gender - matched controls. CONCLUSION: Peripheral BDNF levels are generally reduced in FEP patients. There are some factors that may influence BDNF levels that need to be further studied. Furthermore, a future meta-analysis in this topic is needed.
Authors: Aitor Palomino; Ainara Vallejo-Illarramendi; Ana González-Pinto; Ana Aldama; Cristina González-Gómez; Fernando Mosquera; Gixane González-García; Carlos Matute Journal: Schizophr Res Date: 2006-07-10 Impact factor: 4.939
Authors: Gabriela Favalli; Jennifer Li; Paulo Belmonte-de-Abreu; Albert H C Wong; Zafiris Jeffrey Daskalakis Journal: J Psychiatr Res Date: 2011-10-26 Impact factor: 4.791
Authors: E N Rizos; M Papathanasiou; P G Michalopoulou; A Mazioti; A Douzenis; A Kastania; P Nikolaidou; E Laskos; K Vasilopoulou; L Lykouras Journal: Schizophr Res Date: 2011-04-05 Impact factor: 4.939
Authors: Da Chun Chen; Jing Wang; Bo Wang; Sheng Chang Yang; Chong Xi Zhang; You Lan Zheng; Yan Li Li; Ning Wang; Ke Bing Yang; Mei Hong Xiu; Thomas R Kosten; Xiang Yang Zhang Journal: Psychopharmacology (Berl) Date: 2009-09-29 Impact factor: 4.530
Authors: Monica Aas; Unn K Haukvik; Srdjan Djurovic; Martin Tesli; Lavinia Athanasiu; Thomas Bjella; Lars Hansson; Annamaria Cattaneo; Ingrid Agartz; Ole A Andreassen; Ingrid Melle Journal: J Psychiatr Res Date: 2014-08-30 Impact factor: 4.791
Authors: Brendan P Murphy; Terence Y Pang; Anthony J Hannan; Tina-Marie Proffitt; Mirabel McConchie; Melissa Kerr; Connie Markulev; Colin O'Donnell; Patrick D McGorry; Gregor E Berger Journal: Schizophr Res Treatment Date: 2014-02-05